What Does Research Say About Stem Cell Treatments for Full-Thickness Rotator Cuff Tears?
Published November 16, 2026
Protocol: 7 steps in this guide
The published reviews of cell treatments for full-thickness rotator cuff tears examine cells added during surgical repair, not injections that heal a torn tendon on their own. In that surgical setting, a 2025 meta-analysis of comparative studies found lower retear rates when stem cells were added to repair, but no difference in pain or function. Cell products for rotator cuff tears remain investigational, they are not FDA-approved for this use, and no study cited here shows that an injection closes a full-thickness tear without surgery.
What a full-thickness tear is
The rotator cuff is a group of tendons that hold the top of the arm bone in the shoulder socket. A partial tear damages part of the tendon’s thickness. A full-thickness tear goes all the way through, leaving a gap. For a full-thickness tear, a central research question is whether a repaired tendon stays attached. The American Academy of Orthopaedic Surgeons’ 2025 rotator cuff clinical practice guideline notes, in a strong recommendation, that patients with full-thickness tears can improve with physical therapy, while tear size, muscle atrophy and fatty infiltration may progress over 5 to 10 years.
Surgical and non-surgical care
Treatment depends on the person and the tear. Physical therapy, injections for pain and surgical repair are all used. The AAOS guideline addresses platelet-rich plasma (PRP) separately for each setting, and its recommendations do not transfer between them:
- Without surgery: “Evidence suggests that the routine use of PRP in the non-operative management of full-thickness rotator cuff tears may not be indicated.”
- During repair: platelet-derived augmentation is “not recommended for improving patient-reported outcomes,” with limited evidence that liquid PRP lowers retear rates; this is covered in whether PRP can improve healing after rotator cuff repair.
How cell augmentation is used in trials
In the cuff studies reviewed here, “stem cell treatment” means a cell preparation, such as bone marrow aspirate concentrate (BMAC), applied at the repair site during surgery. A 2025 systematic review in Arthroscopy (Carola and colleagues), “Bone Marrow Aspirate Concentrate May Improve Healing and Function in Rotator Cuff Repair,” found “significant heterogeneity among the included studies in terms of study design, patient demographics, surgical techniques, and methods of BMAC preparation and application.” BMAC itself is covered in what bone marrow aspirate concentrate is.
| Approach | What is compared | Evidence in the sources here |
|---|---|---|
| Cell injection alone for a full-thickness tear | Injection vs no injection or other care | No study identified in the sources cited here |
| Surgery plus cell augmentation | Repair with cells vs repair alone | 2025 meta-analysis of 5 comparative studies; 2025 systematic review |
| Surgery alone | Standard repair | The comparison group in those studies |
Pain and function versus retear on MRI
The 2025 meta-analysis in JSES International, Combined arthroscopic rotator cuff repair with mesenchymal stem cell augmentation shows similar functional outcomes but a higher structural integrity rate compared with isolated repair, pooled 5 comparative studies with 415 patients, 203 with cell augmentation and 212 with repair alone, followed for about 17.5 months on average. It found:
- Retear: 17.7% with cell augmentation versus 35% with repair alone, a significant difference.
- Pain and function: no significant differences in pain scores, range of motion or UCLA shoulder scores.
The authors concluded: “Pain and functional outcomes were similar between the two groups.” The Arthroscopy review was more mixed on retear: one study found no difference between bone marrow concentrate and control, and another found better healing at 6 months and 10 years. Of its two comparative studies, “neither was able to show a difference in PROMs,” meaning patient-reported outcomes. It reported no complications associated with BMAC use. This is the same pattern seen with PRP: a better structural result on imaging without a clear gain in how patients feel.
Why partial-tear and PRP guidance differ
Partial tears and tendinopathy are a different problem from a full-thickness gap. For them, the AAOS guideline states: “The routine use of platelet rich plasma is not supported for the treatment of rotator cuff tendinopathy or partial tears.” Non-surgical PRP for the painful cuff is covered in what is known about PRP for rotator cuff tendinopathy. A study of cells in one setting says little about another.
Quality of control groups and adjuncts
Several features limit the cell evidence:
- The 2025 meta-analysis pooled “comparative studies,” not only randomized trials.
- Cell preparations, surgical techniques and follow-up varied.
- Some trials combine cells with PRP or other materials, making it hard to say which component did what.
- One author of the Arthroscopy review disclosed consulting for orthopedic companies.
A 2026 systematic review of 21 randomized trials of bone marrow products across orthopedic conditions, Efficacy and safety of bone marrow aspirate and bone marrow aspirate concentrate in orthopedic conditions, found that superiority over comparators “was inconsistent and depended on the clinical condition and treatment strategy.”
Questions before enrolling in a trial
FDA’s patient and consumer information on regenerative medicine therapies states that the unapproved regenerative products it warns about “have not been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis,” and lists shoulder pain among them. If you are offered cells for a cuff tear, ask:
- Is this a surgical repair with cells added, or an injection without repair?
- Is it part of a registered trial with an FDA IND or IDE number?
- What is the cell product, and how is it prepared?
- What is the control treatment?
- Is the main outcome retear on imaging, or how I feel and function?
How registry listings and approvals differ is covered in whether listing a study on ClinicalTrials.gov means a treatment is approved.
Research on stem cells for full-thickness rotator cuff tears tests cells added during surgical repair, where pooled studies suggest fewer retears without better pain or function, and it offers no support for a cell injection as a substitute for repairing the tear.
Add a remark